Company intelligence / Profile preview

Neurodyn Life Sciences Inc.

Vancouver, British Columbia, Canadaneurodyn-inc.com ↗

Ownership: Private
Development stage: Other

Overview

Pre-clinical development of Progranulin/Granulin programs for ALS (first indication) with neuroprotective effects demonstrated in models of TDP-43 pathology; previously developed galantamine prodrug (GLN-1062/Alpha-1062) approved for Alzheimer's via spin-out company Alpha Cognition Inc.

Therapeutic areas: Neurology
Modalities: Small moleculeProteinNatural product
Industry: Biotech

Partnerships

Alpha Cognition Inc. (spin-out for GLN-1062)LifeSci Brands Inc. (co-founded for natural products marketing)

Beyond the preview

Go deeper on Neurodyn Life Sciences Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neurodyn Life Sciences Inc..